Posted by Tejaswi Monday, June 28, 2010
OXIS INTERNATIONAL, INC. is completing a strategic and timely transformation towards its goal of becoming a leading nutraceutiecal, cosmecuetical and therapeutics company.

OXIS was founded in 1966 and for many years focused on diagnostics while developing some of its unique patented compounds and acquiring significant expertise in the field of oxidative stress including ERGO. OXIS is now focusing its business on its rich science background and its related 12 key patents and 7 patent pending applications and other new research.

During the past twelve months, OXIS has made significant strides towards its new objectives including:
    * Divesting all of it diagnostics businesses to strategically focus the business on neutraceuticals, cosmeceuticals and therapeutic compounds,
    * Building a new strong team of Executive Management, Board of Directors, and Scientific Advisory Board,
    * Raising new capital to fund its new strategy, and
    * Increasing the equity value and liquidity of its common stock and regaining Bulletin Board trading status.

Investors and others interested in learning more about OXIS are invited to review the following additional information.

Oxis on Twitter
Oxis on facebook

OXIS’ consumer products strategy addresses very important health concerns including aging and age-related disorders that are increasing with trends in US demographics.  These concerns include:
    * Brain health
    * Immunity against diseases
    * Anti-aging/skin health
    * Inflammation
    * Detoxification
    * Blood sugar regulation

BXT 51072 (OUR LEAD COMPOUND) AND GLUTATHIONE PEROXIDASE (GPX) MIMICKING COMPOUNDS: BXT-51072 is a low molecular weight, orally active, organoselenium catalytic mimic of one of the major cellular protective antioxidant enzyme, glutathione peroxidase (GPx) which uses glutathione as substrate.  BXT-51072 can be taken orally or administered intravenously. In addition to its direct hydrogen peroxide (a central reactive oxygen species) neutralizing capabilities, BXT-51072 regulates secondary inflammatory processes by preventing the activation and release of inflammatory mediators such as cytokines, adhesion molecules and inflammatory enzymes.

OXIS planning two product launches for summer 2010
    * “Ergo-Pur™”  - ERGO-Pur is a pure form of our highly potent multifaceted antioxidant which we anticipate will be used in some cases in concert with:
    * “Ergo-Plex™” – ERGO-Plex is a combination of ERGO plus other functional nutraceutical ingredients directed at Joint Health.

Oxidative stress is caused by the unchecked activities of reactive oxygen species (ROS) and reactive nitrogen species (RNS). Both ROS and RNS are highly reactive, unstable molecules that, in healthy cells, are created and neutralized as part of normal cell life. However, if the production of penny stocks & free radicals and ROS/RNS exceeds the body's natural defense mechanisms, oxidative damage to vital molecules in the body can occur and may lead to cell dysfunction and cell death.  Oxidative stress is also caused by inflammation, exposure to cigarette smoke, pollution, UV light, radiation, certain drugs and other conditions.  Oxidative stress also increases as we age.


Post a Comment

Search MY Website

Subscribe and Receive my Updates

Enter your email address:

Delivered by FeedBurner

Software Solutions

↑ Grab this Headline Animator

My Blog Archive